Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director · President and CEO | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,150,599 |
Reported balance
After 2026-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-16 · Sale · Disposed 47,763 · Balance 5,150,599 F1: 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: 3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 856,044 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 856,044 F3: Securities held in the name of the RTC 2019 Trust dated October 1, 2019. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 856,044 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 856,044 F4: Securities held in the name of the JEC 2019 Trust dated October 1, 2019. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,201,108 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,201,108 F5: Securities held in the name of the Chang 2006 Family Trust |
Filing footnotes · ownership attribution and instrument terms
F1: 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: 3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
F3: Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F4: Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F5: Securities held in the name of the Chang 2006 Family Trust
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kite Pharma, Inc.
Report date October 03, 2017 · Filed October 05, 2017
Section 16 reporting ended · disclosed 2017-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-10-03 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2017-09-11 · Gift · Disposed 375 · Balance 57,048 Row 2 · 2017-09-12 · Gift · Disposed 1,041 · Balance 56,007 Row 3 · 2017-09-13 · Gift · Disposed 157 · Balance 55,850 Row 4 · 2017-09-20 · Gift · Disposed 570 · Balance 55,280 Row 5 · 2017-10-03 · Other · Disposed 16,605 · Balance 38,675 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes. Row 6 · 2017-10-03 · Disposition to issuer · Disposed 38,675 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-10-03 · Disposition to issuer · Disposed 116,750 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F5: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-10-03 · Disposition to issuer · Disposed 56,250 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-10-03 · Disposition to issuer · Disposed 51,563 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F8: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-10-03 · Disposition to issuer · Disposed 23,437 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-10-03 · Disposition to issuer · Disposed 28,919 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F9: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-10-03 · Disposition to issuer · Disposed 37,181 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F9: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.09 · Expires 2026-12-21 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-10-03 · Disposition to issuer · Disposed 90,600 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F10: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person.
F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").
F5: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments.
F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option.
F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio.
F8: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.
F9: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
F10: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2026 Filed Mar 18, 2026 20:05 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 47,763 | $2.47 | $117,974.61 |
DisclosureSEC source: 0001737287-26-000013 · wk-form4_1773864344.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,150,599 F1 · shares: 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: 3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantRestricted Stock Unit · Derivative | 392,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-26-000009 · wk-form4_1770243495.xml · derivative · entry 6 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,586 Underlying: Common Stock · 392,586 shares Expires not disclosed F8 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F8 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F8 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 1,387,931 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001737287-26-000009 · wk-form4_1770243495.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,387,931 Underlying: Common Stock · 1,387,931 shares Expires 2036-02-02 F7 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 95,269 | $1.80 | $171,484.20 |
DisclosureSEC source: 0001737287-26-000009 · wk-form4_1770243495.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,185,862 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 4,562 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:30 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 46,668 | $1.96 | $91,469.28 |
DisclosureSEC source: 0001737287-25-000042 · wk-form4_1742333443.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,276,569 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in one transaction at a single price point of $1.96. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at the price set forth above. F3 · balance_after: Includes 6000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 pursuant to an employee stock purchase program. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:13 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 46,003 | $1.68 | $77,285.04 |
DisclosureSEC source: 0001737287-25-000017 · wk-form4_1738790016.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,317,237 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:10 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 1,952,130 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001737287-25-000004 · wk-form4_1738113042.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,952,130 Underlying: Common Stock · 1,952,130 shares Expires 2035-01-24 F5 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:10 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 552,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-25-000004 · wk-form4_1738113042.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,363,240 F1 · balance_after: Includes 960 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program. Read SEC document |
| May 16, 2024 Filed May 20, 2024 22:01 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 344,828 | $2.90 | $1,000,001.20 |
DisclosureSEC source: 0001593968-24-000714 · primary_01.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,810,106 F1 · shares: These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the "Issuer") in a registered direct offering. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:10 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Tax withholdingCommon Stock | 53,393 | $4.33 | $231,191.69 |
DisclosureSEC source: 0001593968-24-000477 · primary_01.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,465,278 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.29 to $4.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 5,468 shares of the Issuer's common stock acquired by the reporting person on March 15, 2024 pursuant to an employee stock purchase program. Read SEC document |
| January 25, 2024 Filed Jan 31, 2024 22:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 1,123,535 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001593968-24-000192 · primary_01.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,123,535 Underlying: Common Stock · 1,123,535 shares Expires 2034-01-25 F5 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| January 25, 2024 Filed Jan 31, 2024 22:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 317,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000192 · primary_01.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,513,203 F1 · balance_after: Includes 1492 shares of the Issuer's common stock acquired by the reporting person on September 15,2023 pursuant to an employee stock purchase program. Read SEC document |
| March 22, 2023 Filed Mar 25, 2023 00:13 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 1,492,200 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001593968-23-000521 · primary_01.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,492,200 Underlying: Common Stock · 1,492,200 shares Expires 2033-03-22 F5 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 22, 2023 Filed Mar 25, 2023 00:13 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 1,924,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-000521 · primary_01.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,193,911 F1 · shares: Includes 1,480,357 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Tax withholdingCommon Stock | 22,340 | $5.56 | $124,210.40 |
DisclosureSEC source: 0001737287-23-000025 · primary_doc.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269,447 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.595, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 135 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:51 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 2,195,512 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0001214659-22-004374 · marketforms-55851.xml · derivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,195,512 Underlying: Common Stock · 2,195,512 shares Expires 2032-03-23 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:59 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 23,648 | $7.65 | $180,878.82 |
DisclosureSEC source: 0001214659-22-004085 · marketforms-55821.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,289,652 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.59 to $7.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 1021 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program. Read SEC document |
| May 24, 2021 Filed May 26, 2021 12:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,410 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-21-005927 · marketforms-52929.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,190 Underlying: Common Stock · 27,410 shares Expires 2030-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| May 24, 2021 Filed May 26, 2021 12:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 27,410 | $18.22 | $499,410.20 |
DisclosureSEC source: 0001214659-21-005927 · marketforms-52929.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,312,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:57 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 298,836 | $0.00 Strike: $33.78 | $0.00 |
DisclosureSEC source: 0001214659-21-003609 · marketforms-52127.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,836 Underlying: Common Stock · 298,836 shares Expires 2031-03-26 F4 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:57 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 80,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003609 · marketforms-52127.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,284,869 Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 20,513 | $38.57 | $791,270.51 |
DisclosureSEC source: 0001214659-21-003240 · marketforms-51920.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,204,417 F1 · kind: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.97 to $38.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 276 shares of the Issuer's common stock acquired by the reporting person on September 15, 2020 and includes 553 shares of the Issuer's common stock acquired by the reporting person on March 15, 2021 pursuant to an employee stock purchase program. Read SEC document |
| August 31, 2020 Filed Apr 2, 2021 20:11 UTC Amendment | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GiftCommon Stock | 205,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003892 · marketforms-52165.xml · nonDerivative · entry 4 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 856,044 F4 · kind: On August 31, 2020, Robert Chang transferred 205,778 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary. F5 · ownership.nature: Securities held in the name of the RTC 2019 Trust dated October 1, 2019. Read SEC document |
| August 31, 2020 Filed Apr 2, 2021 20:11 UTC Amendment | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GiftCommon Stock | 205,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003892 · marketforms-52165.xml · nonDerivative · entry 3 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 856,044 F2 · kind: On August 31, 2020, Julia Chang transferred 205,778 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary. F3 · ownership.nature: Securities held in the name of the JEC 2019 Trust dated October 1, 2019. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003819 · marketforms-48643.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,224,101 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003819 · marketforms-48643.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,201,108 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:37 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 568,600 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-20-002806 · marketforms-48390.xml · derivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,600 Underlying: Common Stock · 568,600 shares Expires 2030-03-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2020 Filed Apr 28, 2020 20:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GiftCommon Stock | 428,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003819 · marketforms-48643.xml · nonDerivative · entry 4 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 650,266 F6 · kind: On March 18, 2020, the Robert Chang 2018 Irrevocable Trust transferred 428,022 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary. F7 · ownership.nature: Securities held in the name of the RTC 2019 Trust dated October 1, 2019. Read SEC document |
| March 18, 2020 Filed Apr 28, 2020 20:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GiftCommon Stock | 428,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003819 · marketforms-48643.xml · nonDerivative · entry 3 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 650,266 F4 · kind: On March 18, 2020, the Julia Chang 2018 Irrevocable Trust transferred 428,022 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary. F5 · ownership.nature: Securities held in the name of the JEC 2019 Trust dated October 1, 2019. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:31 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 1,625 | $20.06 | $32,603.03 |
DisclosureSEC source: 0001214659-20-002734 · marketforms-48339.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,214,914 F1 · kind: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F4 · balance_after: Includes 1,113 shares of the Issuer's common stock acquired by the reporting person on March 16, 2020 pursuant to an employee stock purchase program. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:31 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 18,710 | $19.24 | $360,012.21 |
DisclosureSEC source: 0001214659-20-002734 · marketforms-48339.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,215,426 F1 · kind: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.88 to $19.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 04, 2020 Filed Mar 11, 2020 20:38 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002528 · marketforms-48290.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,234,136 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| March 04, 2020 Filed Mar 11, 2020 20:38 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002528 · marketforms-48290.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,191,910 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:38 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-007333 · marketforms-46372.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,224,745 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:38 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-007333 · marketforms-46372.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,182,508 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:08 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006703 · marketforms-45997.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,215,354 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:08 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006703 · marketforms-45997.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,173,106 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 22:27 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006021 · marketforms-45834.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,205,963 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. F4 · balance_after: Includes 1,103 shares of the Issuer's common stock acquired by the reporting person on September 13, 2019 pursuant to an employee stock purchase program. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 22:27 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006021 · marketforms-45834.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,163,704 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 22:03 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-005741 · marketforms-45712.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,195,469 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 22:03 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-005741 · marketforms-45712.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,154,302 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. The reporting person resigned as Trustee of the Julia Chang 2018 Irrevocable Trust and the Robert Chang 2018 Irrevocable Trust and no longer has a reportable beneficial interest in the 1,696,044 shares included in the reporting person's prior ownership reports. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 20:26 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-042874 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,186,078 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 20:26 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 9,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-042874 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,144,900 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 21:10 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 6,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041955 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,176,687 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| June 18, 2019 Filed Jul 12, 2019 21:10 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 10,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041955 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,135,498 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 11,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030076 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,125,344 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 23:22 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 11,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026676 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,113,591 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:19 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 292,700 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001209191-19-019755 · doc4.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,700 Underlying: Common Stock · 292,700 shares Expires 2029-03-12 F4 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:19 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 173,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019755 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168,625 Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 21:30 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | ConversionSeries A Convertible Preferred Stock · Derivative | 5,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-055374 · doc4.xml · derivative · entry 5 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 29,946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.